Up 7.5% in a week! Is the GSK share price about to do an AstraZeneca?

When I first started writing for The Motley Fool more than two decades ago, the GSK (LSE: GSK) share price was a FTSE 100 shining light. In my recollection, GlaxoSmithKline, as it was known then, even outshone pharmaceutical sector rival AstraZeneca (LSE: …

AstraZeneca’s share price is down 20% from September, so is it time for me to buy?

AstraZeneca’s (LSE: AZN) share price has fallen significantly from its 3 September one-year traded high of £133.38. Some of this drop resulted from an investigation of its Chinese business. The firm said in its Q1 2025 results released on 29 April that …

AstraZeneca Faces Intensified Probe in China as Tax Evasion Amount Grows

British-Swedish pharmaceutical giant AstraZeneca plc is facing increasing scrutiny in China, with authorities accusing the company of evading more than $1.6 million in import taxes as part of a widening smuggling investigation that now includes a top- …

AstraZeneca wins set-aside in Germany

Munich, Germany (Credit: Shutterstock/Sven Hansche) A Munich court has granted AstraZeneca’s petition to set aside a German Arbitration Institute (DIS) award worth US$46.4 million in favour of the former owners of a cancer diagnostics start-up.  …

AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some breast cancer patients. Truqap was approved by the FDA in late 2023 to be used alongside AstraZeneca’s Faslodex to treat a narrower- …

Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC

The FDA has recently approved AstraZeneca’s Imfinzi (durvalumab) for perioperative use in cisplatin-eligible muscle-invasive bladder cancer (MIBC), based on the Phase III NIAGARA trial. With its practice-changing regimen, Imfinzi is the first immunotherapy …

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China

AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

AstraZeneca is discontinuing the late-stage CAPItello-280 trial, which was evaluating its AKT blocker Truqap in patients with metastatic castration-resistant prostate cancer, the pharma announced on Tuesday. The study, which combined Truqap with docetaxel …

AstraZeneca's highly touted Truqap flunks another phase 3 trial

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. Alongside its first-quarter earnings report, AZ revealed that an interim …

AstraZeneca has plenty coming down the pipeline to appease the bears

AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company’s longer-term potential …